Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). [electronic resource]
Producer: 20180502Description: 1024-1031 p. digitalISSN:- 1463-1326
- Aged
- Diabetes Mellitus, Type 2 -- blood
- Double-Blind Method
- Drug Administration Schedule
- Drug Monitoring
- Drug Resistance
- Drug Therapy, Combination
- Female
- Glucagon-Like Peptide-1 Receptor -- antagonists & inhibitors
- Glucagon-Like Peptides -- administration & dosage
- Glycated Hemoglobin -- analysis
- Humans
- Hyperglycemia -- prevention & control
- Hypoglycemia -- chemically induced
- Hypoglycemic Agents -- administration & dosage
- Immunoglobulin Fc Fragments -- administration & dosage
- Incretins -- administration & dosage
- Injections, Subcutaneous
- Insulin Glargine -- administration & dosage
- Intention to Treat Analysis
- Male
- Middle Aged
- Patient Dropouts
- Recombinant Fusion Proteins -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.